Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Stryker

Evaluate

Thumbnail
February 10, 2023

Seven plus eight makes six for Globus

The purchase of Nuvasive for $3.1bn is the biggest ortho deal for some time – and integration will be tough.

Thumbnail
November 18, 2022

Big medtechs’ efficiency starts to recover from Covid

Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.

Article image
Vantage logo
July 04, 2022

Medtech research spending set to slow in 2022

And some diagnostics groups are forecast to actually cut R&D outlay this year as the pandemic eases.

Article image
Vantage logo
June 20, 2022

Up-and-down test sales and a bigger Medtronic: medtech in 2028

Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.

Article image
Vantage logo
May 23, 2022

Diagnostics beat implants in the race to market

Roche had the most innovative approvals over the last five years – but took second place in terms of speed.

Article image
Vantage logo
November 25, 2021

Covid-19 scrambles big medtech’s spending

Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.

Article image
Vantage logo
November 23, 2021

Healthineers scores big in the third quarter

Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.

Article image
Vantage logo
November 19, 2021

Covid-19 takes its toll on medtechs’ efficiency

Staffing levels changed little across 2020 as M&A slowed – but sales are another story.

Article image
Vantage logo
August 24, 2021

Big medtech convalesces after Covid-19

What goes down must come up.

Article image
Vantage logo
February 24, 2021

Medtech’s haves and have-nots

Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.

Article image
Vantage logo
February 08, 2021

Zimmer ditches slow-growing business to refocus

And the move will shake up the orthopaedic robotics scene.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up